No Data
No Data
Possible Turnaround For Humacyte Insiders, Still Down US$412k
HUMACYTE Earnings Preview: Recent $HUMA Insider Trading, Hedge Fund Activity, and More
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $7.5
Humacyte Announces Symvess Cost-Saving Benefits In Journal Of Medical Economics; Supports Economic Value For Hospitals And Payers
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Cuts Target Price to $7.5
Humacyte's SYMVESS Launch and Strategic Positioning Drive Buy Rating